Sunday, August 30, 2015 4:28:23 PM
1) Zoptarelin doxorubicin was developed by Andrew V. Schally while at the Tulane University School of Medicine, New Orleans and subsequently at the Sylvester Comprehensive Cancer Center, University of Miami.
The U.S. Food and Drug Administration (FDA) has granted it orphan drug status for ovarian cancer and endometrial cancer.
https://en.wikipedia.org/wiki/Zoptarelin_doxorubicin
About Andrew Schally
https://en.wikipedia.org/wiki/Andrew_Schally
2) AEZS~ August 25, NEW presentation!
http://www.aezsinc.com/pdfdyn/AEZS%20Presentation%20AUG_25-2015-FINAL.pdf
3) AEZS fact sheet august 2015
http://www.aezsinc.com/pdfdyn/FACT-SHEET-ENG-August-2015%20Final.pdf
4) AEZS~ huge success in Prostate Cancer trial!
A phase I trial in prostate cancer indicated that nine out ten evaluable patients achieved disease stabilization through administration of zoptarelin doxorubicin.
https://en.wikipedia.org/wiki/Zoptarelin_doxorubicin
http://clincancerres.aacrjournals.org/content/20/24/6277
follow me on BLUE SKY BREAKOUT
Recent AEZS News
- Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris • GlobeNewswire Inc. • 03/28/2024 11:55:00 AM
- Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris • GlobeNewswire Inc. • 03/28/2024 11:55:00 AM
- Aeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency • GlobeNewswire Inc. • 03/27/2024 12:05:00 PM
- Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings • GlobeNewswire Inc. • 03/12/2024 06:10:53 PM
- Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings • GlobeNewswire Inc. • 03/12/2024 06:10:00 PM
- Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company • GlobeNewswire Inc. • 02/26/2024 12:30:00 PM
- Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company • GlobeNewswire Inc. • 02/26/2024 12:30:00 PM
- Aeterna Zentaris Issues Letter to Shareholders and Management Proxy Circular Ahead of Special Meeting of Shareholders to Approve Merger of Equals with Ceapro • GlobeNewswire Inc. • 02/15/2024 10:50:00 PM
- Form F-1 - Registration statement for certain foreign private issuers • Edgar (US Regulatory) • 02/15/2024 09:54:45 PM
- Form 20-F/A - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: [Amend] • Edgar (US Regulatory) • 02/15/2024 02:33:18 PM
- Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend] • Edgar (US Regulatory) • 12/22/2023 09:42:20 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/14/2023 12:50:09 PM
- Aeterna Zentaris and Ceapro Announce Merger of Equals to Create a Diversified Biopharmaceutical Company • GlobeNewswire Inc. • 12/14/2023 12:50:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/09/2023 01:05:28 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/09/2023 01:05:15 PM
- Aeterna Zentaris Reports Third Quarter 2023 Financial Results • GlobeNewswire Inc. • 11/09/2023 01:00:00 PM
- Aeterna Zentaris to Participate at the Virtual Investor Ask the CEO Conference • GlobeNewswire Inc. • 10/11/2023 12:00:00 PM
- Aeterna Zentaris to Present at the H.C. Wainwright 25th Annual Global Investment Conference • GlobeNewswire Inc. • 09/05/2023 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/09/2023 12:05:31 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/09/2023 12:05:18 PM
- Aeterna Zentaris Reports Second Quarter 2023 Financial Results • GlobeNewswire Inc. • 08/09/2023 12:05:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/13/2023 11:30:15 AM
- Aeterna Zentaris Outlines Progress on Development Pipeline Programs and Provides Corporate Update • GlobeNewswire Inc. • 07/13/2023 11:30:00 AM
- Aeterna Zentaris to Participate in the Virtual Investor Summer Spotlight Series • GlobeNewswire Inc. • 07/05/2023 12:45:00 PM
- Aeterna Zentaris Announces Results of Virtual 2023 Meeting of Shareholders • GlobeNewswire Inc. • 06/14/2023 08:05:00 PM
FEATURED Glucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring • Apr 17, 2024 8:00 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM
Maybacks Global Entertainment To Fire Up 24 New Stations in Louisiana • AHRO • Apr 16, 2024 1:30 PM
Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • BLOZF • Apr 16, 2024 8:52 AM
Kona Gold Beverages, Inc. Acquires Surge Distribution LLC from Loud Beverage Group, Inc. (LBEV) • KGKG • Apr 16, 2024 8:30 AM
Branded Legacy, Inc. Reports Significant Net Income of Over $3.8 Million • BLEG • Apr 16, 2024 8:30 AM